Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group

• Autores: Maiztegui, Julio I.; McKee Jr, Kelly T.; Barrera Oro, Julio G.; Harrison, Lee H; Gibbs, P H; Feuillade, María Rosa; Enria, Delia; Briggiler, Ana M.; Levis, Silvana; Ambrosio, Ana María; Halsey, Neal A.; Peters, Clarence J.
• Año de publicación: 1998
• Idioma: inglés
• Tipo de recurso: artículo
• Fuente: Journal of infectious diseases 1998; 177(2):277-83.
• Materia: Fiebre Hemorrágica Americana; Arenavirus; Virus Junin
• Institución: Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"

Fil: Maiztegui, Julio I. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.
Fil: McKee Jr, K. T. Womack Army Medical Center, Fort Bragg, North Carolina; Estados Unidos.
Fil: Barrera Oro, J G. ANLIS Dr.C.G.Malbrán; Argentina.
Fil: Harrison, L H. University of Pittsburgh Graduate School of Public Health,Pittsburgh, Pennsylvania; Estados Unidos.
Fil: Gibbs, P H. Division of Disease Assessment, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21701; Estados Unidos.
Fil: Feuillade, María Rosa. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.
Fil: Enria, Delia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.
Fil: Briggiler, Ana M. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.
Fil: Levis, Silvana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.
Fil: Ambrosio, Ana María. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.
Fil: Halsey, N A. Department of International Health, Johns Hopkins Medical Institutions, Baltimore, Maryland; Estados Unidos.
Fil: Peters, C J. Special Pathogens Branch, Centers for Disease Control, Atlanta, Georgia; Estados Unidos.
Argentine hemorrhagic fever (AHF), caused by the arenavirus Junin, is a major public health problem among agricultural workers in Argentina. A prospective, randomized, double-blind, placebo-controlled, efficacy trial of Candid 1, a live attenuated Junin virus vaccine, was conducted over two consecutive epidemic seasons among 6500 male agricultural workers in the AHF-endemic region. Twenty-three men developed laboratory-confirmed AHF during the study; 22 received placebo and 1 received vaccine (vaccine efficacy 95%; 95% confidence interval [CI], 82%-99%). Three additional subjects in each group developed laboratory-confirmed Junin virus infection associated with mild illnesses that did not fulfill the clinical case definition for AHF, yielding a protective efficacy for prevention of any illness associated with Junin virus infection of 84% (95% CI, 60%-94%). No serious adverse events were attributed to vaccination. Candid 1, the first vaccine for the prevention of illness caused by an arenavirus, is safe and highly efficacious.